Mr. Robert Steen reports

PHARMADRUG INC. ENGAGES INVESTOR RELATIONS AND MARKETING SERVICE PROVIDERS

Pharmadrug Inc. has entered into: (i) a marketing and distribution services agreement with an arm's-length marketing firm, Outside The Box Capital Inc. (OTBC), to provide marketing services, including digital marketing services through various social media channels to broaden media distribution awareness about the company; (ii) a services agreement with CanaCom Group to design, develop and execute a company awareness program for the company; and (iii) a consulting services agreement with Candid Capital Corp. to complete a marketing campaign for the company.

Outside the Box

OTBC will also feature the company in different influencer-based videos and highlight videos surrounding recent company news through platforms, including Reddit, Discord, Telegram, Twitter and StockTwits. In addition, OTBC will spread company insights and announcements to new communities with hopes of attracting new investors and other interested parties for the company through various social media platforms. The marketing services provided by OTBC are expected to create increased company awareness and investor engagement amongst its current and prospective shareholders. The OTCB agreement will have a term of six months starting on Feb. 8, 2024, and Pharmadrug will pay OTBC a cash fee of $100,000 plus applicable taxes. OTBC holds approximately 2.3 per cent of the company's outstanding common shares and is otherwise an arm's-length service provider to the company. OTBC has its principal place of business at 2202 Green Orchard Pl., Oakville, Ont. It can be contacted at jason@outsidethebox.capital or by telephone at 289-259-4455.

CanaCom

Pursuant to the terms of the CanaCom agreement, the services are to be provided over a 12-month period, commencing on Feb. 12, 2024, for a fee of $100,000, plus applicable taxes. CanaCom is a full-service marketing agency based in Toronto, Ont. CanaCom provides digital marketing awareness through advertising through its fully owned platform, theDeepDive.ca, which includes both video and written content coverage of Canadian small-cap stories. CanaCom holds approximately 2.3 per cent of the company's outstanding common shares and is otherwise an arm's-length service provider to the company. CanaCom has its principal place of business at 1836 Scarth St., Regina, Sask., S4P 3G3. It can be contacted at jay@thedeepdive.ca or by telephone at 306-993-4791.

Candid Capital

Pursuant to the terms of the Candid agreement, the services are to be provided over a four-month period, commencing on Feb. 12, 2024, for a fee of $35,398.24, plus applicable taxes. Candid Capital based in Toronto, Ont., and provides capital market consulting. Candid Capital will provide an investor awareness campaign through phone calls to certain investment dealers, institutional investors and family offices as well as the implementation of an e-mail communication strategy and the co-ordination of the company's marketing vendors. CanaCom holds less than 1 per cent of the company's outstanding common shares and is otherwise an arm's-length service provider to the company. CanaCom has its principal place of business at 800 King St. W, Suite 801, Toronto, Ont., M5V 3M7. It can be contacted at jd@candidcapital.com or by telephone at 416-887-5467.

About Pharmadrug Inc.

Pharmadrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled substances and natural medicines such as psychedelics and previously approved drugs. Pharmadrug owns 51 per cent of Sairiyo Therapeutics, a biotechnology company that specializes in researching and reformulating established natural medicines with a goal of bringing them through clinical trials and the associated regulatory approval process in the United States and Europe. Sairiyo is currently developing its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious diseases and rare cancers. Pharmadrug also owns 100 per cent of SecureDose Synthetics Inc., a pharmaceutical research and development company focused on the development of synthetic formulations of currently existing drugs for potential commercialization and distribution.

We seek Safe Harbor.